Incretin Atlas › Trials › OASIS 4
OASIS 4
Semaglutide · obesity
Design
- Molecule(s)
- Semaglutide
- Population
- obesity
- Official title
- Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2022-10 → 2024-04
- Participants
- 307
- Duration
- 64 weeks
- Registry
- NCT05564117
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| oral semaglutide 25 mg | obesity | 64 | 307 | −16.6 % vs −2.7 % Δ −13.9 pp | −13.6 % vs −2.2 % Δ −11.4 pp | −0.3 vs −0.1 | 6.9 vs 5.9 | 18.5 vs 25.5 | 46.6 vs 18.6 | 30.9 vs 5.9 | 3.9 vs 8.8 | −6.8 vs −5.4 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (7)
- oral semaglutide 25 mg · ae_dc · Table 3
Adverse events leading to discontinuation of semaglutide or placebo 14 (6.9) 14 5.6 6 (5.9)
- oral semaglutide 25 mg · disc_any · Results, Participants
243 participants (79.2%) were receiving sema- glutide or placebo at the end of the 64-week trial period — 167 (81.5%) in the oral semaglutide group and 76 (74.5%) in the placebo group; 290
- oral semaglutide 25 mg · nausea · Table 3
Nausea 95 (46.6) 157 62.5 19 (18.6) 27 22.2
- oral semaglutide 25 mg · vomiting · Table 3
Vomiting 63 (30.9) 105 41.8 6 (5.9) 6 4.9
- oral semaglutide 25 mg · sae · Table 3
Serious adverse events 8 (3.9) 17 6.8 9 (8.8) 13 10.7
- oral semaglutide 25 mg · hba1c · Table 2
Glycated hemoglobin — percentage points –0.3 –0.1 –0.2 (–0.3 to –0.2)
- oral semaglutide 25 mg · sbp · Table 2
Systolic blood pressure — mm Hg –6.8 –5.4 –1.4 (–4.6 to 1.8)
Primary sources
- Novo Nordisk A/S. Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity (OASIS 4). ClinicalTrials.gov identifier NCT05564117. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05564117
- Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077-1087. PMID: 40934115.
How to cite this page
Medical Adviser's Group. Incretin Atlas: OASIS 4. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/oasis-4/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.